AU2009325147B2 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt - Google Patents

11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt Download PDF

Info

Publication number
AU2009325147B2
AU2009325147B2 AU2009325147A AU2009325147A AU2009325147B2 AU 2009325147 B2 AU2009325147 B2 AU 2009325147B2 AU 2009325147 A AU2009325147 A AU 2009325147A AU 2009325147 A AU2009325147 A AU 2009325147A AU 2009325147 B2 AU2009325147 B2 AU 2009325147B2
Authority
AU
Australia
Prior art keywords
salt
shows
hci
batch
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009325147A
Other languages
English (en)
Other versions
AU2009325147A1 (en
Inventor
Brian Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sobi Inc
Original Assignee
Sobi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sobi Inc filed Critical Sobi Inc
Publication of AU2009325147A1 publication Critical patent/AU2009325147A1/en
Assigned to CELL THERAPEUTICS, INC. reassignment CELL THERAPEUTICS, INC. Request for Assignment Assignors: S*BIO PTE LTD
Assigned to CTI BIOPHARMA CORP. reassignment CTI BIOPHARMA CORP. Amend patent request/document other than specification (104) Assignors: CELL THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2009325147B2 publication Critical patent/AU2009325147B2/en
Assigned to SOBI, INC. reassignment SOBI, INC. Request to Amend Deed and Register Assignors: CTI BIOPHARMA CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
AU2009325147A 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt Active AU2009325147B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121,668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (2)

Publication Number Publication Date
AU2009325147A1 AU2009325147A1 (en) 2011-06-23
AU2009325147B2 true AU2009325147B2 (en) 2014-08-14

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009325147A Active AU2009325147B2 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Country Status (23)

Country Link
US (2) US8980873B2 (enExample)
EP (1) EP2376499B1 (enExample)
JP (1) JP5669748B2 (enExample)
KR (1) KR101729918B1 (enExample)
CN (1) CN102282148B (enExample)
AR (2) AR074724A1 (enExample)
AU (1) AU2009325147B2 (enExample)
BR (1) BRPI0922736B1 (enExample)
CA (1) CA2746058C (enExample)
DK (1) DK2376499T3 (enExample)
ES (1) ES2536558T3 (enExample)
HR (1) HRP20150428T1 (enExample)
IL (3) IL213418A0 (enExample)
MX (1) MX2011006206A (enExample)
MY (1) MY160005A (enExample)
NZ (1) NZ593223A (enExample)
PL (1) PL2376499T3 (enExample)
PT (1) PT2376499E (enExample)
RU (1) RU2527970C2 (enExample)
SG (1) SG171907A1 (enExample)
TW (1) TWI449705B (enExample)
WO (1) WO2010068181A1 (enExample)
ZA (1) ZA201104032B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.
EP2376500B1 (en) * 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
PL2837632T3 (pl) 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
HRP20030911A2 (en) * 2001-05-14 2004-02-29 Pfizer Prod Inc Citrate salt 5,8,14,-triazatetracyclo (10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>)-hexadeca-2 (11), 3,5,7,9-pentaene
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
KR20040066140A (ko) * 2001-11-29 2004-07-23 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
MX2011006206A (es) 2008-12-11 2011-07-20 S Bio Pte Ltd Sal de citrato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26- triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5 ,8,10,12(27),16,21,23-decaeno.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
CN102282148A (zh) 2011-12-14
PL2376499T3 (pl) 2015-07-31
WO2010068181A8 (en) 2011-08-18
EP2376499A1 (en) 2011-10-19
BRPI0922736B1 (pt) 2022-02-22
CA2746058A1 (en) 2010-06-17
AR114133A2 (es) 2020-07-22
AU2009325147A1 (en) 2011-06-23
NZ593223A (en) 2013-08-30
SG171907A1 (en) 2011-07-28
ES2536558T3 (es) 2015-05-26
TW201028426A (en) 2010-08-01
BRPI0922736A2 (pt) 2017-10-31
RU2011126173A (ru) 2013-01-20
PT2376499E (pt) 2015-06-03
MX2011006206A (es) 2011-07-20
AR074724A1 (es) 2011-02-09
IL250310A0 (en) 2017-03-30
US20110294831A1 (en) 2011-12-01
IL289379A (en) 2022-02-01
CN102282148B (zh) 2014-12-24
CA2746058C (en) 2016-05-17
DK2376499T3 (en) 2015-05-04
JP5669748B2 (ja) 2015-02-12
IL213418A0 (en) 2011-07-31
WO2010068181A1 (en) 2010-06-17
HK1161877A1 (en) 2012-08-10
HRP20150428T1 (xx) 2015-06-19
JP2012511571A (ja) 2012-05-24
RU2527970C2 (ru) 2014-09-10
US9624242B2 (en) 2017-04-18
KR20110106344A (ko) 2011-09-28
KR101729918B1 (ko) 2017-04-25
ZA201104032B (en) 2012-08-29
US20150322084A1 (en) 2015-11-12
BRPI0922736A8 (pt) 2021-11-09
MY160005A (en) 2017-02-15
TWI449705B (zh) 2014-08-21
EP2376499B1 (en) 2015-02-25
US8980873B2 (en) 2015-03-17

Similar Documents

Publication Publication Date Title
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
US9624242B2 (en) 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
EP2376500B1 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
CN102762577B (zh) 9e-15-(2-吡咯烷-1-基-乙氧基)-7,12,25-三氧杂-19,21,24-三氮杂-四环[18.3.1.1(2,5).1(14,18)]二十六碳-1(24),2,4,9,14,16,18(26),20,22-壬烯柠檬酸盐
HK1161877B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELL THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): S*BIO PTE LTD

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: SOBI, INC.

Free format text: FORMER NAME(S): CTI BIOPHARMA CORP.